Grant: Alliance Grants
University of British Columbia
$50,000.00
Development of aerosolized encapsulated recombinant ACE2 for treating COVID-19 early symptom patients_x000d_ _x000d_ _x000d_ _x000d_
EF 2020-21
Résumé
COVID-19 has generated a global pandemic due to lack of effective vaccine and reliable clinically tested treatments. With more than 5 million people infected globally, the number of deaths surpassed 325 thousand globally, and 6 thousand in Canada by mid-May 2020, and is expected to increase. Most global medical research efforts are currently focused on the creation of a vaccine, expected to be available in at least 12 months. Attention has also been dedicated to the treatment of intensive care unit (ICU) patients with lung tissue damage. However, infected people who are starting to show typical initial symptoms, are being overlooked in both global and Canadian efforts. Large parts of the world are unable to provide adequate testing for the public at large due to a shortage of tests or components thereof. Without adequate and timely treatment, these patients eventually evolve into ICU patients, potentially overwhelming our healthcare system. The possibility of containment of the virus reproduction rate in patients experiencing typical early symptoms is the main inspiration behind this proposal.
The team of experts from the University of British Columbia (across Faculties of Land & Food Systems, Science, Applied Science, Mechanical Engineering, and Medicine), the St. Paul's Sinus Centre (Center of Heart and Lung Innovation), BC, and the Woolcock Institute of Medical Research (University of Sydney), Australia, in partnership with equipment manufacturer Enwave Inc., BC, proposes to develop a breathable decoy: inhalable microparticles using encapsulated recombinant Angiotensin-converting enzyme 2 (rhACE2) that binds to the virus-receptors. These microparticles will be designed to be released inside the respiratory tract of early symptoms patients, via inhalers, to bind to the virus surface before the virus reaches the target. Our solution does not aim to be a vaccine for Covid-19, rather aims to exploit the virus-receptor affinity to create a solution to treat the symptoms of SARS-CoV-2 infection.
Programme
Alliance Grants
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
554607-2020
Name nom
Pratap Singh, Anubhav
Department département
Land and Food Systems, Faculty of
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
50000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
500
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Manufacturing processes and products
Area of application fr
Procédés et produits industriels
Research subject code
6400
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Life sciences research related to human health and disease
Research subject fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Development of aerosolized encapsulated recombinant ACE2 for treating COVID-19 early symptom patients_x000d_
_x000d_
_x000d_
_x000d_
Keyword
NSERC
Application summary
COVID-19 has generated a global pandemic due to lack of effective vaccine and reliable clinically tested treatments. With more than 5 million people infected globally, the number of deaths surpassed 325 thousand globally, and 6 thousand in Canada by mid-May 2020, and is expected to increase. Most global medical research efforts are currently focused on the creation of a vaccine, expected to be available in at least 12 months. Attention has also been dedicated to the treatment of intensive care unit (ICU) patients with lung tissue damage. However, infected people who are starting to show typical initial symptoms, are being overlooked in both global and Canadian efforts. Large parts of the world are unable to provide adequate testing for the public at large due to a shortage of tests or components thereof. Without adequate and timely treatment, these patients eventually evolve into ICU patients, potentially overwhelming our healthcare system. The possibility of containment of the virus reproduction rate in patients experiencing typical early symptoms is the main inspiration behind this proposal.
The team of experts from the University of British Columbia (across Faculties of Land & Food Systems, Science, Applied Science, Mechanical Engineering, and Medicine), the St. Paul's Sinus Centre (Center of Heart and Lung Innovation), BC, and the Woolcock Institute of Medical Research (University of Sydney), Australia, in partnership with equipment manufacturer Enwave Inc., BC, proposes to develop a breathable decoy: inhalable microparticles using encapsulated recombinant Angiotensin-converting enzyme 2 (rhACE2) that binds to the virus-receptors. These microparticles will be designed to be released inside the respiratory tract of early symptoms patients, via inhalers, to bind to the virus surface before the virus reaches the target. Our solution does not aim to be a vaccine for Covid-19, rather aims to exploit the virus-receptor affinity to create a solution to treat the symptoms of SARS-CoV-2 infection.